Doctors In Maine Say Halt In OxyContin Marketing Comes ’20 Years Late’

Doctors In Maine Say Halt In OxyContin Marketing Comes '20 Years Late'

Bottles of Purdue Pharma L.P. OxyContin medication

sit on a pharmacy shelf in Provo, Utah, in 2016.George Frey/Bloomberg via Getty Images.The maker of OxyContin, one of the most prescribed and aggressively marketed opioid painkillers, will no longer tout the drug or any other opioids to doctors.The announcement, made Saturday, came as drugmaker Purdue Pharma faces lawsuits for deceptive marketing brought by cities and counties across the U.S., including several in Maine. The company said it's cutting its U.S. sales force by more than half.

Just how important are these steps against the backdrop of a raging opioid epidemic that took the lives of more than 300 Maine residents in 2016, and accounted for more than 42,000 deaths nationwide?

"They're 20 years late to the game," says Dr. Noah Nesin, a family physician and vice president of medical affairs at Penobscot Community Health Care. Nesin says even after Purdue Pharma paid $600 million in fines about a decade ago for misleading doctors and regulators about the risks opioids posed for addiction and abuse, it continued marketing them. "I think it's similar to the tobacco industry learning they could sell tobacco without spending a lot of money on advertising. My guess is this decision is in their self-interest," he says.

A nationwide lawsuit against Purdue Pharma for deceptive marketing continues to grow. Seven cities in Maine have joined, including Portland, Lewiston and Bangor, along with five counties, to recoup some of the costs of addressing the addiction crisis. A spokesman for Purdue Pharma said in an email that the decision to stop marketing to prescribers is voluntary and independent of any litigation. Nesin says that at the very least, the company's decision to refrain from promoting opioids to doctors reinforces the need for caution when prescribing the drugs.

Maine Medical Association President Dr. Robert Schlager agrees that Purdue Phama's move is a good, if small, step to fight the opioid epidemic. "I wouldn't expect it to have a very large role in limiting opioids further," he says. "Because most of us, as prescribers, do limit our information exchange with the drug representatives who have been marketing opioids."